The New England journal of medicine
-
Randomized Controlled Trial Comparative Study Clinical Trial
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
Mutations in the tumor-suppressor gene VHL cause oversecretion of vascular endothelial growth factor by clear-cell renal carcinomas. We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma. ⋯ Bevacizumab can significantly prolong the time to progression of disease in patients with metastatic renal-cell cancer.
-
Letter Case Reports
Fatal aspergillosis in a patient with SARS who was treated with corticosteroids.